More than 29 million people in the United States and 420 million globally have diabetes, with a projected global prevalence of 642 million by 2040.1,2 This accelerating pandemic comes with high personal and financial costs to the individual, society, and the economy. The expanding number of antihyperglycemic medication options for type 2 diabetes, often involving different mechanisms of action and safety profiles, can be a challenge for clinicians, and the increasing complexity of diabetes management requires a well-informed strategy for prevention and treatment of this disease.
Jane E. B. Reusch, JoAnn E. Manson. Management of Type 2 Diabetes in 2017Getting to Goal. JAMA. 2017;317(10):1015–1016. doi:10.1001/jama.2017.0241